Weekly Paclitaxel, Carboplatin, Cetuximab (PCC) and Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF), Followed by Risk-based Local Therapy in Previously Untreated Locally Advanced Head and Neck Squamous Cell Carcinoma (LAHNSCC)

Guilherme Rabinowits

Weekly Paclitaxel, Carboplatin, Cetuximab (PCC) and Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF), Followed by Risk-based Local Therapy in Previously Untreated Locally Advanced Head and Neck Squamous Cell Carcinoma (LAHNSCC)

Guilherme Rabinowits

Baptist Health South Florida

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - 2015
Event	2015 ASCO Annual Meeting - Chicago, IL Duration: Jan 1 2015 → …

Conference

Conference	2015 ASCO Annual Meeting
Period	1/1/15 → …

Disciplines

Medicine and Health Sciences

Cite this

@conference{2bce32a8abe443b6af7edd6fe6b4c90e,

title = "Weekly Paclitaxel, Carboplatin, Cetuximab (PCC) and Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF), Followed by Risk-based Local Therapy in Previously Untreated Locally Advanced Head and Neck Squamous Cell Carcinoma (LAHNSCC)",

author = "Guilherme Rabinowits",

year = "2015",

language = "American English",

note = "2015 ASCO Annual Meeting ; Conference date: 01-01-2015",

}

TY - CONF

T1 - Weekly Paclitaxel, Carboplatin, Cetuximab (PCC) and Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF), Followed by Risk-based Local Therapy in Previously Untreated Locally Advanced Head and Neck Squamous Cell Carcinoma (LAHNSCC)

AU - Rabinowits, Guilherme

PY - 2015

Y1 - 2015

M3 - Presentation

T2 - 2015 ASCO Annual Meeting

Y2 - 1 January 2015

ER -